On June 16, WuXi XDC fell 3.02% in regular trading, trading at HK$47.1/share with turnover of HK$82.71 million, extending a multi-session decline that has pushed the stock more than 17% below its buyback average price of HK$57.3.

The continued weakness comes amid persistent sector pressure following the US Department of Defense listing parent group affiliate WuXi AppTec on its 1260H Chinese Military Companies list. WuXi AppTec has since filed a lawsuit in US federal court challenging the designation, but market uncertainty remains elevated. The broader WuXi system deployed approximately US$500 million in combined buybacks, including HK$327 million by WuXi XDC's trustee at an average price of HK$57.3, yet the intensive repurchases have failed to reverse selling pressure. Southbound funds recorded net selling for five consecutive sessions recently, reducing holdings by 3.63 million shares over that period.

Within the Life Sciences Tools and Services sector, WuXi Biologics fell 2.01%, XtalPi fell 3.31%, GenScript Biotech fell 2.71%, and Insilico Medicine fell 4.40%, while WuXi AppTec edged up 0.24%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)